Clinical Research Directory

Inclusion Criteria: 1. Adult patients ( 14 years) 2. Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes. 3. Must have a blood test confirming the presence of at least one autoantibody to pancreatic islet Cells (IAA, IA2, GAD 65, ZnT8). 4. Fasting C-peptide level \> 0.3 ng/ml 5. HbA1C \< 10% at enrollment 6. Recent diagnosis (within two years of enrollment) 7. Adequate venous access for apheresis 8. Must be equipped with a continuous glucose monitoring system (CGMS) 9. Ability to provide informed consent 10. For female patients only, willingness to use FDA-recommended birth control (http://www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM356451.pdf) until 6 months post treatment. 11. Must agree to comply with all study requirements and be willing to complete all study visits Exclusion Criteria: 1. AST or ALT 2 \> x upper limit of normal. 2. Abnormal bilirubin (total bilirubin \> 1.2 mg/dL, direct bilirubin \> 0.4 mg/dL) 3. Creatinine \> 2.0 mg/dl. 4. Known coronary artery disease or EKG suggestive of coronary artery disease unless cardiac clearance for apheresis is obtained from a cardiologist. 5. Known active infection such as Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) 6. Pregnancy assessed by a positive serum pregnancy test or breastfeeding mothers 7. Use of immunosuppressive medication within one month of enrollment including but not limited to prednisone, cyclosporine, tacrolimus, sirolimus, and chemotherapy. 8. Presence of any other autoimmune diseases (lupus, rheumatoid arthritis, scleroderma, etc.) 9. Anticoagulation other than ASA. 10. Hemoglobin \< 10 g/dl or platelets \< 100 k/ml 11. Is unable or unwilling to provide informed consent 12. Presence of any other physical or psychological medical condition that, in the opinion of the investigator, would preclude participation